Tyra Biosciences Stock
Tyra Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Todd Harris
- Employees
- 87
- Market cap
- $1.1 B
- IPO
- 15/09/2021
- Web
- www.tyra.bio
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company headquartered in Carlsbad, California, focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. The company's flagship product candidate is TYRA-300, which is a highly selective inhibitor of the fibroblast…
Company description based on the data provider's company data, AI-assisted, created on 17/10/2026. Not investment advice.
Tyra Biosciences stock: price history
1D
-2.7%
1W
-7.1%
1M
-23.9%
6M
-47.9%
YTD
-29.6%
1Y
+24.8%
2Y
-28.5%
5Y
+13.3%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~11% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Tyra Biosciences
Analyst assessment of Tyra Biosciences
PRICE TARGET LOW
US$29.00
CONSENSUS
US$43.40
MEDIAN
US$42.00
PRICE TARGET HIGH
US$56.00
0
STRONG BUY
7
BUY
0
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 22/09/2026
Tyra Biosciences stock metrics
P/E
-7.72
P/B
3.46
EV/EBITDA
-7
RETURN ON EQUITY
-12.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
74.3%
FLOAT SHARES
44,328,145
AVG. DAILY VOLUME (30D)
1,193,932
Insider transactions (SEC)
Fuhrman Alan
Rueb Yuliya
Harris Todd
Verjee Rehan
Rueb Yuliya
Institutional holders
Comparable stocks
Frequently asked questions about Tyra Biosciences stock
What does Tyra Biosciences do?
Tyra Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Todd Harris, the company employs around 87 people.
The IPO was on 15/09/2021; the stock trades on NASDAQ under the ticker TYRA.
What do analysts say about Tyra Biosciences stock?
7 analysts rate the stock, the consensus is Buy (as of 22/09/2026).
The average price target is US$43.40, ranging from US$29.00 to US$56.00, with a median of US$42.00.
This is an external assessment, not a statement by Market Jury.
When does Tyra Biosciences report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 11% stronger than usual.
Does Tyra Biosciences pay a dividend?
No, Tyra Biosciences currently does not pay a dividend.
Which stocks are comparable to Tyra Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Tyra Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Tyra Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.